September 27th, 2010
Promising Results for New DES in Peripheral Disease
Larry Husten, PHD
A new drug-eluting stent designed to treat peripheral disease showed promising results in the largest trial yet of endovascular treatment in this population. The 12-month results of the Zilver PTX randomized trial comparing a novel paclitaxel-eluting stent versus balloon angioplasty and bare-metal stenting in patients with symptomatic above-the-knee femoropopliteal artery disease were presented at TCT2010 by Michael Dake. […]
NEJM Journal Watch — Recent Cardiology Articles- Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long Is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction